Additionally, several studies have reported that GHET1 can promote EMT in esophageal squamous cell carcinoma, breast cancer, colorectal cancer, osteosarcoma, renal cell carcinoma, and bladder cancer [17, 18, 22, 31, 33, 34]. Here, GHET1 is linked to breast carcinoma.